Search Results - "BAIZE, N"

Immunotherapy in renal cell carcinoma: A booming clinical research by Baize, N, Bigot, P

“…Nivolumab, an anti-PD1 immune control point inhibitor, is the first treatment that has improved the overall survival of patients after first-line metastatic…”
Get more information

Correlation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): The CIROCO study by Desrame, J., Loup Mouysset, J., Altwegg, T., Zelek, L., Baize, N.

Get full text

Impact of partial nephrectomy in a hybrid operating room on the activity of kidney cancer surgery by Aubert, C, Rolley, C, Mauny, M, Heuveline, J, Silve, E, Humeau, M, Le Corre, V, Lebdai, S, Brassart, E, Culty, T, Baize, N, Rousselet, M C, Nedelcu, C, Aubé, C, Bouvier, A, Bigot, P

“…Partial nephrectomy (NP) after embolization of tumor vessels (NPESH) in a hybrid room combines embolization of tumor vessels and enucleation of the tumor under…”
Get more information

Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST study by Fontaine-Delaruelle, C., Mazières, J., Cadranel, J., Mastroianni, B., Dubos-Arvis, C., Dumont, P., Monnet, I., Pichon, E., Locatelli-Sanchez, M., Dixmier, A., Coudert, B., Fraboulet, S., Foucher, P., Dansin, E., Baize, N., Vincent, M., Missy, P., Morin, F., Moro-Sibilot, D., Couraud, S.

“…Lung cancer in women is on the rise, with a higher proportion occurring in lifelong never-smokers. Lung cancer in never-smokers (LCINS) exhibits a high…”
Get full text

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study by Auliac, J. B., Fournier, C., Audigier Valette, C., Perol, M., Bizieux, A., Vinas, F., Decroisette Phan van Ho, C., Bota Ouchlif, S., Corre, R., Le Garff, G., Fournel, P., Baize, N., Lamy, R., Vergnenegre, A., Arpin, D., Marin, B., Chouaid, C., Gervais, R.

“…Retrospective studies suggested a benefit of first-line tyrosine kinase inhibitor (TKI) treatment continuation after response evaluation in solid tumors…”
Get full text

Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens by Baize, N, Abakar-Mahamat, A, Mounier, N, Berthier, F, Caroli-Bosc, F. X

“…Purpose To determine the safety and the efficacy of paclitaxel and capecitabine as second-line combination chemotherapy after failure of platinum regimens in…”
Get full text

Bone metastasis from endometrioid ovarian carcinoma: a case study and literature review by Baize, N, Mahamat, A, Benizri, E, Saint-Paul, M C, Mounier, N

“…Bone metastases from epithelial ovarian carcinoma are rare, usually discovered postmortem. The survival of these patients is poor. Furthermore, only two cases…”
Get more information

Delayed partial nephrectomy following complete response to immunotherapy: Feasibility and results (UroCCR n°157) by Margue, G., Parier, B., Albiges, L., Klein, C., Pignot, G., Gravis, G., Bigot, P., Baize, N., Ingels, A., Charlotte, J., Audenet, F., Vano, Y., Waeckel, T., Levard, R., Gross-Goupil, M., Bernhard, J.C.

Get full text

A0832 - Delayed partial nephrectomy following complete response to immunotherapy: Feasibility and results (UroCCR n°157) by Margue, G., Parier, B., Albiges, L., Klein, C., Pignot, G., Gravis, G., Bigot, P., Baize, N., Ingels, A., Charlotte, J., Audenet, F., Vano, Y., Waeckel, T., Levard, R., Gross-Goupil, M., Bernhard, J.C.

Get full text

1790PCorrelation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): The CIROCO study by Desrame, J, Loup Mouysset, J, Altwegg, T, Zelek, L, Baize, N

Get full text

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial by Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J.P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P.J., Langlais, A., Morin, F., Zalcman, G., Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., Raspaud, C.

“…IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after chemotherapy induction did not improve outcomes in extensive SCLC patients. This…”
Get full text

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) by Chang, A., Manegold, C., Douillard, J.-Y., Malik, R., Giaccone, G., Begbie, S., Jennens, R., Tzekova, V., Couture, F., Hirsh, V., Burkes, R., Sangha, R., Ambrus, M., Janaskova, T., Musil, J., Jakesova, J., Roubec, J., Vanasek, J., Barlesi, F., Bennouna-Louridi, J., Chouaid, C., Robinet, G., Souquet, P.-J., Spaeth, D., Schott, R., Lena, H., Baize, N., Molinier, O., Fuchs, F., Marschner, N., Schuette, W., Syrigos, K., Papandreou, C., Bocskei, C., Juhasz, E., Losonczy, G., Mark, Z., Molnar, I., Papai-Szekely, Z., Tehenes, S., Vinkler, I., Maru, A., Pathak, A., Prasad, S.V.S.S., Kilara, N., Gorijavolu, D., John, S., Amoroso, D., Bajetta, E., Bonetti, A., Maio, M., Passalacqua, R., Bitina, M., Brize, A., Purkalne, G., Skrodele, M., Samson-Fernando, M.C., Jassem, J., Koralewski, P., Cebotaru, C., Ganea-Motan, D.E., Ianuli, C.H., Manolescu, I.G., Udrea, A., Burdaeva, O., Filippov, A., Lazarev, S., Tan, Y.O., Bastus Piulats, R., Garcia-Foncillas, J., Valdivia, J., de Castro, J., Lee, J.-S., Lee, J.S., Shin, S.W., Kim, Y.-C., Chang, G.-C., Goan, Y.-G., Kuo, H.-P., Demir, G., Crawford, J., Giaccone, G., Agarwal, M., Pandit, S., Araujo, R., Vrindavanam, N., Bonomi, P., Wade, J., Camidge, R., Hill, D., Rarick, M., Flynn, P., Savin, M., Richards, D., Dangoor, A., Summers, Y., Rankin, E., Rowley, K., Kristeleit, H., Taylor, P.

“…Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced…”
Get full text

Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 – REGOLD by Aparicio, Thomas, Darut-Jouve, Ariane, Khemissa Akouz, Faiza, Montérymard, Carole, Artru, Pascal, Cany, Laurent, Romano, Olivier, Valenza, Bruno, Le Foll, Christine, Delbaldo, Catherine, Falandry, Claire, Norguet Monnereau, Emmanuelle, Ben Abdelghani, Meher, Smith, Denis, Rinaldi, Yves, Père Verge, Denis, Baize, Nathalie, Maillard, Emmanuel, Dohan, Anthony, Des Guetz, Gaetan, Pamoukdjian, Frédéric, Lepage, Come

“…Regorafenib significantly increases overall survival (OS) in patients with metastatic colorectal cancer previously treated but gives toxicities. to assess the…”
Get full text

The combination of everolimus and zoledronic acid increase the efficacy of gemcitabine in a mouse model of pancreatic adenocarcinoma by Vitellius, Carole, Fizanne, Lionel, Menager-Tabourel, Elodie, Nader, Joelle, Baize, Nathalie, Laly, Margot, Lermite, Emilie, Bertrais, Sandrine, Caroli-Bosc, F X

“…Gemcitabine is a standard treatment for pancreatic adenocarcinoma. Many mechanisms are involved in gemcitabine resistance, such as reduced expression of the…”
Get full text

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies by MORAN, T, WEI, J, CHAIB, I, YOU, C, MASSUTI, B, SONG, Y, VERGNENEGRE, A, LU, H, LOPEZ-VIVANCO, G, HU, W, ROBINET, G, YAN, J, COBO, M, INSA, A, XU, X, MAJEM, M, CHEN, X, DE LAS PENAS, R, KARACHALIOU, N, SALA, M. A, WU, Q, ISLA, D, ZHOU, Y, QIAN, X, BAIZE, N, ZHANG, F, GARDE, J, GERMONPRE, P, RAUH, S, ALHUSAINI, H, SANCHEZ-RONCO, M, DROZDOWSKYJ, A, SANCHEZ, J. J, CAMPS, C, DOMINE, M, LIU, B, ROSELL, R, ZOU, Z, BOVER, I, WANG, L, PROVENCIO, M, YU, L

“…In a Spanish Lung Cancer Group (SLCG) phase II trial, the combination of BRCA1 and receptor-associated protein 80 (RAP80) expression was significantly…”
Get full text

Traitement des cancers bronchiques à petites cellules métastatiques en 2012 by Baize, N.

“…Systemic chemotherapy plays a major role in the management of patients with Stage IV small-cell lung cancer(SCLC). Despite strong initial chemosensitivity,…”
Get full text

Lung Cancer in Patients Under 40 Years: a Prospective Observational Multicenter Study (Groupe Français De Pneumo-Cancérologie (Gfpc) 1001 Study) by Bigay-Gamé, L., Bota, S., Greillier, L., Monnet, I., Madroszyk, A., Corre, R., Mastroianni, B., Falchero, L., Chouaid, C., Audigier-Valette, C., Baize, N., Daniel, C., Fraboulet, G., Gossot, D., Raynaud, C., Mazières, J., Colineaux, H., Lepage, B., Robinet, G.

Get full text

1565PLUNG CANCER IN PATIENTS UNDER 40 YEARS: A PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY (GROUPE FRANÇAIS DE PNEUMO-CANCÉROLOGIE (GFPC) 1001 STUDY) by Bigay-Gamé, L., Bota, S., Greillier, L., Monnet, I., Madroszyk, A., Corre, R., Mastroianni, B., Falchero, L., Chouaid, C., Audigier-Valette, C., Baize, N., Daniel, C., Fraboulet, G., Gossot, D., Raynaud, C., Mazières, J., Colineaux, H., Lepage, B., Robinet, G.

“…Abstract Aim: Lung cancer in patients under 40 years is infrequent and few data are available about the presentation and outcomes of lung cancer in this…”
Get full text

Traitement des cancers bronchiques à petites cellules métastatiques en 2012 : Les cancers bronchiques by BAIZE, N

Get full text

1287PRETROSPECTIVE MULTICENTER STUDY IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION TREATED FIRST-LINE TYROSINE KINASE INHIBITOR (TKI): EVALUATION OF PROGRESSION ACCORDING TO RECIST, THERAPEUTIC APPROACH AND ITS EFFECT by Auliac, J.B., Fournier, C., Valette, C. Audigier, Perol, M., Bizieux, A., Monnet, I., van Ho, C. Decroisette Phan, Ouchlif, S. Bota, Corre, R., Garff, G. Le, Fournel, P., Baize, N., Lamy, R., Vergnenegre, A., Arpin, D., Marin, B., Greillier, L., Gervais, R.

“…Abstract Aim: Background: EGFR-TKI are a standard treatment for patients (pts) with NSCLC harboring activating EGFR mutations. All pts develop acquired…”
Get full text